# Direct oral anticoagulants (DOACs)

Drug · id `cardio:direct-oral-anticoagulants-doacs` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Direct oral anticoagulants; Direct-acting oral anticoagulants

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

Direct oral anticoagulants are blood thinners taken by mouth. Each of the three US drug labels read for this page names its medicine as one of the direct-acting oral anticoagulants (DOACs). The labels describe two ways of working: two of the medicines block clotting factor Xa, and the third blocks thrombin directly. All three labels list lowering the risk of stroke, and of clots elsewhere in the body, in non-valvular atrial fibrillation among their uses, and all three carry a boxed warning about stopping early. This is the class page: each medicine has its own page.

## Technical summary

Class page. MeSH heading D065427, Factor Xa Inhibitors, is a broad match only: it covers the factor Xa blockers and leaves out the direct thrombin inhibitor. The labels read are those of three products, two factor Xa inhibitors and one direct thrombin inhibitor. The warnings section of each names its product among the direct-acting oral anticoagulants (DOACs); every other statement is scoped to its own product. No trial result and no dose is recorded here.

## Connected pages

- Files under this front: Medicines (`cardio:front-medicines`)
- The US label names the direct-acting oral anticoagulants (DOACs) as a group of anticoagulants: Anticoagulants (`cardio:anticoagulants`)
- Strategy page for oral anticoagulants in atrial fibrillation: Blood thinners (oral anticoagulants) to prevent stroke in AF (`cardio:oral-anticoagulation`)
- A medicine with its own page: Apixaban (`cardio:apixaban`)
- A medicine with its own page: Dabigatran (`cardio:dabigatran`)
- A medicine with its own page: Edoxaban (`cardio:edoxaban`)
- A medicine with its own page: Rivaroxaban (`cardio:rivaroxaban`)
- Related condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Related to: Post-thrombotic syndrome (`cardio:post-thrombotic-syndrome`)
- Related to: Blood thinners (oral anticoagulants) to prevent stroke in AF (`cardio:oral-anticoagulation`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry trial

## Provenance

Content hash: f161b34ef59a2b548ccd4362ee9dcdc2cf9582248ba275f2a6507d266eecb02d
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
